| 1 |
31564004 | Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study. | 2020 Mar |
1 |
| 2 |
30971225 | Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study). | 2019 Apr 11 |
1 |
| 3 |
31262916 | Flutamide as an Alternative Anti-androgen Agent and Predictor of the Efficacy of Novel Androgen Receptor-targeted Agents. | 2019 Jul |
6 |
| 4 |
29843816 | Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide. | 2018 May 29 |
4 |
| 5 |
27123292 | Clinical outcomes of anti-androgen withdrawal and subsequent alternative anti-androgen therapy for advanced prostate cancer following failure of initial maximum androgen blockade. | 2016 May |
1 |
| 6 |
27493956 | Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade. | 2016 |
4 |
| 7 |
26024831 | A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. Bicalutamide. | 2015 Aug |
1 |
| 8 |
22180287 | Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. | 2012 Sep 1 |
1 |
| 9 |
19239458 | Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up. | 2009 Aug |
1 |
| 10 |
19389135 | Suppression of mutant androgen receptors by flutamide. | 2009 May |
1 |
| 11 |
18497080 | Characterization of androgen regulation of ZEB-1 and PSA in 22RV1 prostate cancer cells. | 2008 |
2 |
| 12 |
15661065 | Small cell carcinoma of the prostate with hypercalcemia. | 2005 Jan |
1 |
| 13 |
16153201 | A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. | 2005 Oct |
1 |
| 14 |
16153202 | Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. | 2005 Oct |
1 |
| 15 |
16275987 | Imaging androgen receptor function during flutamide treatment in the LAPC9 xenograft model. | 2005 Nov |
1 |
| 16 |
15223852 | Flutamide administration at 500 mg daily has similar effects on serum testosterone to 750 mg daily. | 2004 Jul-Aug |
1 |
| 17 |
14616448 | The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer. | 2003 Nov |
3 |
| 18 |
14624911 | Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. | 2003 Nov |
3 |
| 19 |
14635088 | Indole-3-carbinol induces a G1 cell cycle arrest and inhibits prostate-specific antigen production in human LNCaP prostate carcinoma cells. | 2003 Dec 1 |
1 |
| 20 |
11316974 | Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist. | 2001 |
3 |
| 21 |
11706524 | Inhibition of PSA flare in prostate cancer patients by administration of flutamide for 2 weeks before initiation of treatment with slow-releasing LH-RH agonist. | 2001 Feb |
7 |
| 22 |
10634368 | Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women. | 2000 Jan |
1 |
| 23 |
10705202 | Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma. | 2000 Feb |
3 |
| 24 |
11062382 | Comparative study of the clinical efficacy of two dosing regimens of flutamide. | 2000 Fall |
1 |
| 25 |
11085345 | Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance. | 2000 Nov |
1 |
| 26 |
11095136 | A prospective randomized multicenter study of chlormadinone acetate versus flutamide in total androgen blockade for prostate cancer. | 2000 Sep |
1 |
| 27 |
10851326 | Long-Term Combined Androgen Blockade Alone for Localized Prostate Cancer. | 1999 |
2 |
| 28 |
9634122 | Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression. | 1998 Jun |
2 |
| 29 |
9750522 | [Antiandrogen withdrawal syndrome]. | 1998 Aug |
1 |
| 30 |
9112515 | Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. | 1997 May |
7 |
| 31 |
9144890 | The antiandrogen withdrawal syndrome. | 1997 |
1 |
| 32 |
9186348 | Is prednisolone as good as flutamide in hormone refractory metastatic carcinoma of the prostate? | 1997 Jul |
3 |
| 33 |
9187700 | Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. | 1997 Jun |
2 |
| 34 |
9224356 | Re: Characterization of patients with androgen independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. | 1997 Aug |
1 |
| 35 |
9471771 | [The antiandrogen withdrawal syndrome: decrease in prostate specific antigen serum levels after withdrawal of antiandrogens]. | 1997 Sep |
1 |
| 36 |
8558675 | Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. | 1996 Feb |
12 |
| 37 |
8973674 | Combined finasteride and flutamide therapy in men with advanced prostate cancer. | 1996 Dec |
3 |
| 38 |
8995493 | A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response. | 1996 |
1 |
| 39 |
7535978 | Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. | 1995 Apr |
1 |
| 40 |
7541862 | Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. | 1995 Aug |
5 |
| 41 |
8620419 | The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. | 1995 Oct 15 |
2 |
| 42 |
7510915 | Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. | 1994 Mar |
1 |
| 43 |
7679759 | Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. | 1993 Mar |
2 |
| 44 |
1948117 | Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. | 1991 Oct |
1 |
| 45 |
1693455 | Prostate-specific antigen in prostatic carcinoma. | 1990 |
1 |